Retooling treatment in oligometastatic oesophageal cancer

The existence of a true oligometastatic disease state and its optimal management across solid tumours remains controversial. As long-term survival improves in oesophageal squamous cell carcinoma, primarily due to the use of immune checkpoint inhibitors (ICIs), gauging the benefit of adding local treatment of metastases to systemic therapy becomes a clinically relevant question.1,2